Fiduciary Alliance LLC Has $3.27 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Fiduciary Alliance LLC cut its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,655 shares of the medical research company’s stock after selling 1,874 shares during the period. Fiduciary Alliance LLC’s holdings in Edwards Lifesciences were worth $3,266,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. DSM Capital Partners LLC bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $28,000. Turtle Creek Wealth Advisors LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at $34,000. Riverview Trust Co bought a new stake in Edwards Lifesciences in the 1st quarter valued at $34,000. Pingora Partners LLC bought a new stake in Edwards Lifesciences in the 4th quarter valued at $38,000. Finally, SRS Capital Advisors Inc. lifted its position in shares of Edwards Lifesciences by 292.6% during the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 474 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $92.42, for a total value of $2,712,527.00. Following the completion of the sale, the director now owns 4,486 shares in the company, valued at approximately $414,596.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $94.89, for a total value of $688,426.95. Following the completion of the transaction, the chief financial officer now owns 19,074 shares of the company’s stock, valued at approximately $1,809,931.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the completion of the sale, the director now owns 4,486 shares in the company, valued at $414,596.12. The disclosure for this sale can be found here. In the last quarter, insiders sold 127,104 shares of company stock worth $11,267,464. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW traded down $0.97 on Friday, reaching $92.37. 11,670,925 shares of the company’s stock traded hands, compared to its average volume of 2,666,729. The firm has a market cap of $55.66 billion, a price-to-earnings ratio of 39.81, a P/E/G ratio of 3.38 and a beta of 1.11. The stock has a 50 day moving average price of $87.85 and a 200-day moving average price of $85.30. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Equities research analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent research reports. StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Thursday. Mizuho upped their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Oppenheimer increased their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Piper Sandler raised their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a report on Friday, April 26th. Finally, Stifel Nicolaus increased their price target on Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $95.06.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.